Antiviral Drugs on the Treatment of SARS-CoV-2

NCT04727775 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-08-02

No results posted yet for this study

Summary

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

Conditions

  • Complication of Medical Care
  • Pneumonia, Viral

Interventions

DRUG

Favipiravir

Antiviral drugs

DRUG

Remdesivir

Antiviral drugs

Sponsors & Collaborators

  • Astana Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2023-07-25
Completion
2023-07-25

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04727775 on ClinicalTrials.gov